Major market players in the global diabetic foot ulcer therapeutics market are introducing innovative and expanded line products to retain their global market share. Over the last few decades, an increasing number of diabetic foot ulcer therapeutics manufacturers have been focusing on introducing breakthrough advanced wound dressings for diabetic foot ulcer management. This includes novel dressings with the ability to confer moisture balance with prolonged time of action, extended oxygen permeability, antimicrobial activity, growth factor stimulation, and the ability to promote autolytic debridement thus facilitating the re-epithelialization process. This factor is creating robust development in the global diabetic foot ulcer therapeutics market.
A growing population affected by diabetes and a subsequent increase in the number of people afflicted with diabetic foot ulcer is likely to impact the global diabetic foot ulcer therapeutics market in a positive manner over the forecast period. Furthermore, continued prioritization to avoid surgeries and amputations is expected to fuel the growth of the global diabetic foot ulcer therapeutics market over the predicted period. Diabetes mellitus is one of the most important public health concerns worldwide, with an increased risk of developing diabetic foot ulcer. Hence, a number of clinical trials are being conducted currently wherein a large number of organizations are actively participating in extended research programs to develop novel therapies for diabetic foot ulcer treatment. Individuals with an increased risk of diabetes are demonstrating alarming hospitalization rates as a result of diabetes foot ulcer infection. This has resulted in a rise in the number of amputations. The occurrence of diabetes and associated risk factors are increasing at an alarming rate, which is expected to fuel revenue growth of the global diabetic foot ulcer therapeutics market during the period of assessment.
Market Analysis and Insights: Global Diabetic Foot Ulcer Therapeutics Market
The global Diabetic Foot Ulcer Therapeutics market size is projected to reach US$ 6463.6 million by 2026, from US$ 4355.6 million in 2020, at a CAGR of 6.8% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Diabetic Foot Ulcer Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Diabetic Foot Ulcer Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Diabetic Foot Ulcer Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Diabetic Foot Ulcer Therapeutics market.
Diabetic Foot Ulcer Therapeutics Breakdown Data by Type
Advance Wound Dressings
Skin Substitutes
Negative Pressure Wound Therapy Devices
Growth Factors
Diabetic Foot Ulcer Therapeutics Breakdown Data by Application
Hospitals
Specialty Clinics
Long-Term Care Centers
Ambulatory Surgical Centers
Based on regional and country-level analysis, the Diabetic Foot Ulcer Therapeutics market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Diabetic Foot Ulcer Therapeutics market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The following players are covered in this report:
B.Braun Melsungen
Smith & Nephew
Organogenesis
Derma Sciences
Sigvaris
3M
Acelity
Innocoll Holdings
SIGVARIS
Osiris
A growing population affected by diabetes and a subsequent increase in the number of people afflicted with diabetic foot ulcer is likely to impact the global diabetic foot ulcer therapeutics market in a positive manner over the forecast period. Furthermore, continued prioritization to avoid surgeries and amputations is expected to fuel the growth of the global diabetic foot ulcer therapeutics market over the predicted period. Diabetes mellitus is one of the most important public health concerns worldwide, with an increased risk of developing diabetic foot ulcer. Hence, a number of clinical trials are being conducted currently wherein a large number of organizations are actively participating in extended research programs to develop novel therapies for diabetic foot ulcer treatment. Individuals with an increased risk of diabetes are demonstrating alarming hospitalization rates as a result of diabetes foot ulcer infection. This has resulted in a rise in the number of amputations. The occurrence of diabetes and associated risk factors are increasing at an alarming rate, which is expected to fuel revenue growth of the global diabetic foot ulcer therapeutics market during the period of assessment.
Market Analysis and Insights: Global Diabetic Foot Ulcer Therapeutics Market
The global Diabetic Foot Ulcer Therapeutics market size is projected to reach US$ 6463.6 million by 2026, from US$ 4355.6 million in 2020, at a CAGR of 6.8% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Diabetic Foot Ulcer Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Diabetic Foot Ulcer Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Diabetic Foot Ulcer Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Diabetic Foot Ulcer Therapeutics market.
Diabetic Foot Ulcer Therapeutics Breakdown Data by Type
Advance Wound Dressings
Skin Substitutes
Negative Pressure Wound Therapy Devices
Growth Factors
Diabetic Foot Ulcer Therapeutics Breakdown Data by Application
Hospitals
Specialty Clinics
Long-Term Care Centers
Ambulatory Surgical Centers
Based on regional and country-level analysis, the Diabetic Foot Ulcer Therapeutics market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Diabetic Foot Ulcer Therapeutics market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The following players are covered in this report:
B.Braun Melsungen
Smith & Nephew
Organogenesis
Derma Sciences
Sigvaris
3M
Acelity
Innocoll Holdings
SIGVARIS
Osiris
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Diabetic Foot Ulcer Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.2.2 Advance Wound Dressings
1.2.3 Skin Substitutes
1.2.4 Negative Pressure Wound Therapy Devices
1.2.5 Growth Factors
1.3 Market by Application
1.3.1 Global Diabetic Foot Ulcer Therapeutics Market Share by Application: 2020 VS 2026
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.3.4 Long-Term Care Centers
1.3.5 Ambulatory Surgical Centers
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Diabetic Foot Ulcer Therapeutics Market Perspective (2015-2026)
2.2 Global Diabetic Foot Ulcer Therapeutics Growth Trends by Regions
2.2.1 Diabetic Foot Ulcer Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Diabetic Foot Ulcer Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Diabetic Foot Ulcer Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Diabetic Foot Ulcer Therapeutics Players by Market Size
3.1.1 Global Top Diabetic Foot Ulcer Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Diabetic Foot Ulcer Therapeutics Revenue Market Share by Players (2015-2020)
3.2 Global Diabetic Foot Ulcer Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Diabetic Foot Ulcer Therapeutics Revenue
3.4 Global Diabetic Foot Ulcer Therapeutics Market Concentration Ratio
3.4.1 Global Diabetic Foot Ulcer Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Diabetic Foot Ulcer Therapeutics Revenue in 2019
3.5 Key Players Diabetic Foot Ulcer Therapeutics Area Served
3.6 Key Players Diabetic Foot Ulcer Therapeutics Product Solution and Service
3.7 Date of Enter into Diabetic Foot Ulcer Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Diabetic Foot Ulcer Therapeutics Breakdown Data by Type (2015-2026)
4.1 Global Diabetic Foot Ulcer Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Diabetic Foot Ulcer Therapeutics Forecasted Market Size by Type (2021-2026)
5 Diabetic Foot Ulcer Therapeutics Breakdown Data by Application (2015-2026)
5.1 Global Diabetic Foot Ulcer Therapeutics Historic Market Size by Application (2015-2020)
5.2 Global Diabetic Foot Ulcer Therapeutics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Diabetic Foot Ulcer Therapeutics Market Size (2015-2026)
6.2 North America Diabetic Foot Ulcer Therapeutics Market Size by Type (2015-2020)
6.3 North America Diabetic Foot Ulcer Therapeutics Market Size by Application (2015-2020)
6.4 North America Diabetic Foot Ulcer Therapeutics Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Diabetic Foot Ulcer Therapeutics Market Size (2015-2026)
7.2 Europe Diabetic Foot Ulcer Therapeutics Market Size by Type (2015-2020)
7.3 Europe Diabetic Foot Ulcer Therapeutics Market Size by Application (2015-2020)
7.4 Europe Diabetic Foot Ulcer Therapeutics Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic
7.4.7 Rest of Europe
8 China
8.1 China Diabetic Foot Ulcer Therapeutics Market Size (2015-2026)
8.2 China Diabetic Foot Ulcer Therapeutics Market Size by Type (2015-2020)
8.3 China Diabetic Foot Ulcer Therapeutics Market Size by Application (2015-2020)
8.4 China Diabetic Foot Ulcer Therapeutics Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia
8.4.7 Rest of Asia-Pacific
9 Japan
9.1 Japan Diabetic Foot Ulcer Therapeutics Market Size (2015-2026)
9.2 Japan Diabetic Foot Ulcer Therapeutics Market Size by Type (2015-2020)
9.3 Japan Diabetic Foot Ulcer Therapeutics Market Size by Application (2015-2020)
9.4 Japan Diabetic Foot Ulcer Therapeutics Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil
10 Southeast Asia
10.1 Southeast Asia Diabetic Foot Ulcer Therapeutics Market Size (2015-2026)
10.2 Southeast Asia Diabetic Foot Ulcer Therapeutics Market Size by Type (2015-2020)
10.3 Southeast Asia Diabetic Foot Ulcer Therapeutics Market Size by Application (2015-2020)
10.4 Southeast Asia Diabetic Foot Ulcer Therapeutics Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
10.4.4 Rest of Middle East & Africa
11 Key Players Profiles
11.1 B.Braun Melsungen
11.1.1 B.Braun Melsungen Company Details
11.1.2 B.Braun Melsungen Business Overview
11.1.3 B.Braun Melsungen Diabetic Foot Ulcer Therapeutics Introduction
11.1.4 B.Braun Melsungen Revenue in Diabetic Foot Ulcer Therapeutics Business (2015-2020))
11.1.5 B.Braun Melsungen Recent Development
11.2 Smith & Nephew
11.2.1 Smith & Nephew Company Details
11.2.2 Smith & Nephew Business Overview
11.2.3 Smith & Nephew Diabetic Foot Ulcer Therapeutics Introduction
11.2.4 Smith & Nephew Revenue in Diabetic Foot Ulcer Therapeutics Business (2015-2020)
11.2.5 Smith & Nephew Recent Development
11.3 Organogenesis
11.3.1 Organogenesis Company Details
11.3.2 Organogenesis Business Overview
11.3.3 Organogenesis Diabetic Foot Ulcer Therapeutics Introduction
11.3.4 Organogenesis Revenue in Diabetic Foot Ulcer Therapeutics Business (2015-2020)
11.3.5 Organogenesis Recent Development
11.4 Derma Sciences
11.4.1 Derma Sciences Company Details
11.4.2 Derma Sciences Business Overview
11.4.3 Derma Sciences Diabetic Foot Ulcer Therapeutics Introduction
11.4.4 Derma Sciences Revenue in Diabetic Foot Ulcer Therapeutics Business (2015-2020)
11.4.5 Derma Sciences Recent Development
11.5 Sigvaris
11.5.1 Sigvaris Company Details
11.5.2 Sigvaris Business Overview
11.5.3 Sigvaris Diabetic Foot Ulcer Therapeutics Introduction
11.5.4 Sigvaris Revenue in Diabetic Foot Ulcer Therapeutics Business (2015-2020)
11.5.5 Sigvaris Recent Development
11.6 3M
11.6.1 3M Company Details
11.6.2 3M Business Overview
11.6.3 3M Diabetic Foot Ulcer Therapeutics Introduction
11.6.4 3M Revenue in Diabetic Foot Ulcer Therapeutics Business (2015-2020)
11.6.5 3M Recent Development
11.7 Acelity
11.7.1 Acelity Company Details
11.7.2 Acelity Business Overview
11.7.3 Acelity Diabetic Foot Ulcer Therapeutics Introduction
11.7.4 Acelity Revenue in Diabetic Foot Ulcer Therapeutics Business (2015-2020)
11.7.5 Acelity Recent Development
11.8 Innocoll Holdings
11.8.1 Innocoll Holdings Company Details
11.8.2 Innocoll Holdings Business Overview
11.8.3 Innocoll Holdings Diabetic Foot Ulcer Therapeutics Introduction
11.8.4 Innocoll Holdings Revenue in Diabetic Foot Ulcer Therapeutics Business (2015-2020)
11.8.5 Innocoll Holdings Recent Development
11.9 SIGVARIS
11.9.1 SIGVARIS Company Details
11.9.2 SIGVARIS Business Overview
11.9.3 SIGVARIS Diabetic Foot Ulcer Therapeutics Introduction
11.9.4 SIGVARIS Revenue in Diabetic Foot Ulcer Therapeutics Business (2015-2020)
11.9.5 SIGVARIS Recent Development
11.10 Osiris
11.10.1 Osiris Company Details
11.10.2 Osiris Business Overview
11.10.3 Osiris Diabetic Foot Ulcer Therapeutics Introduction
11.10.4 Osiris Revenue in Diabetic Foot Ulcer Therapeutics Business (2015-2020)
11.10.5 Osiris Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Diabetic Foot Ulcer Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.2.2 Advance Wound Dressings
1.2.3 Skin Substitutes
1.2.4 Negative Pressure Wound Therapy Devices
1.2.5 Growth Factors
1.3 Market by Application
1.3.1 Global Diabetic Foot Ulcer Therapeutics Market Share by Application: 2020 VS 2026
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.3.4 Long-Term Care Centers
1.3.5 Ambulatory Surgical Centers
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Diabetic Foot Ulcer Therapeutics Market Perspective (2015-2026)
2.2 Global Diabetic Foot Ulcer Therapeutics Growth Trends by Regions
2.2.1 Diabetic Foot Ulcer Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Diabetic Foot Ulcer Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Diabetic Foot Ulcer Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Diabetic Foot Ulcer Therapeutics Players by Market Size
3.1.1 Global Top Diabetic Foot Ulcer Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Diabetic Foot Ulcer Therapeutics Revenue Market Share by Players (2015-2020)
3.2 Global Diabetic Foot Ulcer Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Diabetic Foot Ulcer Therapeutics Revenue
3.4 Global Diabetic Foot Ulcer Therapeutics Market Concentration Ratio
3.4.1 Global Diabetic Foot Ulcer Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Diabetic Foot Ulcer Therapeutics Revenue in 2019
3.5 Key Players Diabetic Foot Ulcer Therapeutics Area Served
3.6 Key Players Diabetic Foot Ulcer Therapeutics Product Solution and Service
3.7 Date of Enter into Diabetic Foot Ulcer Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Diabetic Foot Ulcer Therapeutics Breakdown Data by Type (2015-2026)
4.1 Global Diabetic Foot Ulcer Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Diabetic Foot Ulcer Therapeutics Forecasted Market Size by Type (2021-2026)
5 Diabetic Foot Ulcer Therapeutics Breakdown Data by Application (2015-2026)
5.1 Global Diabetic Foot Ulcer Therapeutics Historic Market Size by Application (2015-2020)
5.2 Global Diabetic Foot Ulcer Therapeutics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Diabetic Foot Ulcer Therapeutics Market Size (2015-2026)
6.2 North America Diabetic Foot Ulcer Therapeutics Market Size by Type (2015-2020)
6.3 North America Diabetic Foot Ulcer Therapeutics Market Size by Application (2015-2020)
6.4 North America Diabetic Foot Ulcer Therapeutics Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Diabetic Foot Ulcer Therapeutics Market Size (2015-2026)
7.2 Europe Diabetic Foot Ulcer Therapeutics Market Size by Type (2015-2020)
7.3 Europe Diabetic Foot Ulcer Therapeutics Market Size by Application (2015-2020)
7.4 Europe Diabetic Foot Ulcer Therapeutics Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic
7.4.7 Rest of Europe
8 China
8.1 China Diabetic Foot Ulcer Therapeutics Market Size (2015-2026)
8.2 China Diabetic Foot Ulcer Therapeutics Market Size by Type (2015-2020)
8.3 China Diabetic Foot Ulcer Therapeutics Market Size by Application (2015-2020)
8.4 China Diabetic Foot Ulcer Therapeutics Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia
8.4.7 Rest of Asia-Pacific
9 Japan
9.1 Japan Diabetic Foot Ulcer Therapeutics Market Size (2015-2026)
9.2 Japan Diabetic Foot Ulcer Therapeutics Market Size by Type (2015-2020)
9.3 Japan Diabetic Foot Ulcer Therapeutics Market Size by Application (2015-2020)
9.4 Japan Diabetic Foot Ulcer Therapeutics Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil
10 Southeast Asia
10.1 Southeast Asia Diabetic Foot Ulcer Therapeutics Market Size (2015-2026)
10.2 Southeast Asia Diabetic Foot Ulcer Therapeutics Market Size by Type (2015-2020)
10.3 Southeast Asia Diabetic Foot Ulcer Therapeutics Market Size by Application (2015-2020)
10.4 Southeast Asia Diabetic Foot Ulcer Therapeutics Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
10.4.4 Rest of Middle East & Africa
11 Key Players Profiles
11.1 B.Braun Melsungen
11.1.1 B.Braun Melsungen Company Details
11.1.2 B.Braun Melsungen Business Overview
11.1.3 B.Braun Melsungen Diabetic Foot Ulcer Therapeutics Introduction
11.1.4 B.Braun Melsungen Revenue in Diabetic Foot Ulcer Therapeutics Business (2015-2020))
11.1.5 B.Braun Melsungen Recent Development
11.2 Smith & Nephew
11.2.1 Smith & Nephew Company Details
11.2.2 Smith & Nephew Business Overview
11.2.3 Smith & Nephew Diabetic Foot Ulcer Therapeutics Introduction
11.2.4 Smith & Nephew Revenue in Diabetic Foot Ulcer Therapeutics Business (2015-2020)
11.2.5 Smith & Nephew Recent Development
11.3 Organogenesis
11.3.1 Organogenesis Company Details
11.3.2 Organogenesis Business Overview
11.3.3 Organogenesis Diabetic Foot Ulcer Therapeutics Introduction
11.3.4 Organogenesis Revenue in Diabetic Foot Ulcer Therapeutics Business (2015-2020)
11.3.5 Organogenesis Recent Development
11.4 Derma Sciences
11.4.1 Derma Sciences Company Details
11.4.2 Derma Sciences Business Overview
11.4.3 Derma Sciences Diabetic Foot Ulcer Therapeutics Introduction
11.4.4 Derma Sciences Revenue in Diabetic Foot Ulcer Therapeutics Business (2015-2020)
11.4.5 Derma Sciences Recent Development
11.5 Sigvaris
11.5.1 Sigvaris Company Details
11.5.2 Sigvaris Business Overview
11.5.3 Sigvaris Diabetic Foot Ulcer Therapeutics Introduction
11.5.4 Sigvaris Revenue in Diabetic Foot Ulcer Therapeutics Business (2015-2020)
11.5.5 Sigvaris Recent Development
11.6 3M
11.6.1 3M Company Details
11.6.2 3M Business Overview
11.6.3 3M Diabetic Foot Ulcer Therapeutics Introduction
11.6.4 3M Revenue in Diabetic Foot Ulcer Therapeutics Business (2015-2020)
11.6.5 3M Recent Development
11.7 Acelity
11.7.1 Acelity Company Details
11.7.2 Acelity Business Overview
11.7.3 Acelity Diabetic Foot Ulcer Therapeutics Introduction
11.7.4 Acelity Revenue in Diabetic Foot Ulcer Therapeutics Business (2015-2020)
11.7.5 Acelity Recent Development
11.8 Innocoll Holdings
11.8.1 Innocoll Holdings Company Details
11.8.2 Innocoll Holdings Business Overview
11.8.3 Innocoll Holdings Diabetic Foot Ulcer Therapeutics Introduction
11.8.4 Innocoll Holdings Revenue in Diabetic Foot Ulcer Therapeutics Business (2015-2020)
11.8.5 Innocoll Holdings Recent Development
11.9 SIGVARIS
11.9.1 SIGVARIS Company Details
11.9.2 SIGVARIS Business Overview
11.9.3 SIGVARIS Diabetic Foot Ulcer Therapeutics Introduction
11.9.4 SIGVARIS Revenue in Diabetic Foot Ulcer Therapeutics Business (2015-2020)
11.9.5 SIGVARIS Recent Development
11.10 Osiris
11.10.1 Osiris Company Details
11.10.2 Osiris Business Overview
11.10.3 Osiris Diabetic Foot Ulcer Therapeutics Introduction
11.10.4 Osiris Revenue in Diabetic Foot Ulcer Therapeutics Business (2015-2020)
11.10.5 Osiris Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
